PMID- 18814932 OWN - NLM STAT- MEDLINE DCOM- 20090507 LR - 20210208 IS - 0169-5002 (Print) IS - 0169-5002 (Linking) VI - 64 IP - 1 DP - 2009 Apr TI - Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: Fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients. PG - 66-70 LID - 10.1016/j.lungcan.2008.07.016 [doi] AB - BACKGROUND: In this study, we sought to evaluate the prognostic importance of chromosomal instability (CIN) in adenocarcinoma (AC) of the lung. The relationship between CIN detected by fluorescence in situ hybridization (FISH) and survival in AC patients was examined. METHODS: Sixty-three surgical specimens of lung AC were analyzed. To identify tumors with CIN, p16 and multi-target DNA FISH assays for c-myc, chromosome 6, EGFR, and chromosome 5 (LAVysion, Vysis) were performed on nuclei extracted from paraffin-embedded tumor tissues. Survival rates were compared in terms of sex, age, histology, T factor, N factor, CIN, and smoking status. A sample was classified as CIN-positive if at least three of the five chromosomes were positive. RESULTS: Out of the 63 specimens, 32 (39.7%) were CIN-positive. The 5-year overall disease-free survival rate was 58.7% as a whole, 46.9% for CIN-positive patients and 71.0% for the CIN-negative patients [hazard ratio (HR), 2.34; 95% confidence interval (CI), 1.04-5.26; p = 0.04]. The 5-year overall survival rate was 81.0%, 68.7% for CIN-positive patients and 93.5% for the CIN-negative patients (HR, 5.64; 95% CI, 1.23-25.70; p = 0.026). In multivariate analysis after adjusting for pathologic nodal staging, tumor staging, sex, age, and smoking history, compared with the CIN-negative patients, the CIN-positive status remained significantly associated with decreased overall survival (HR, 8.48; 95% CI, 1.66-43.42; p = 0.010). CONCLUSIONS: CIN can be effectively detected in primary AC of lung using FISH analysis. CIN is associated with poor prognosis for AC, and may thus be utilized as an independent prognostic factor for the disease. FAU - Choi, Chang-Min AU - Choi CM AD - Department of Internal Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea. FAU - Seo, Kwang Won AU - Seo KW FAU - Jang, Se Jin AU - Jang SJ FAU - Oh, Yeon-Mok AU - Oh YM FAU - Shim, Tae-Sun AU - Shim TS FAU - Kim, Woo Sung AU - Kim WS FAU - Lee, Dong-Soon AU - Lee DS FAU - Lee, Sang-Do AU - Lee SD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080923 PL - Ireland TA - Lung Cancer JT - Lung cancer (Amsterdam, Netherlands) JID - 8800805 RN - 0 (CDKN2A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (MYC protein, human) RN - 0 (Neoplasm Proteins) RN - 0 (Proto-Oncogene Proteins c-myc) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Adenocarcinoma/*genetics/pathology MH - Adult MH - Aged MH - *Chromosomal Instability MH - Chromosomes, Human, Pair 6/*genetics MH - Cyclin-Dependent Kinase Inhibitor p16 MH - ErbB Receptors/*genetics MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence MH - Korea MH - Lung Neoplasms/*genetics/pathology MH - Male MH - Middle Aged MH - Neoplasm Proteins/*genetics MH - Paraffin Embedding MH - Prognosis MH - Proto-Oncogene Proteins c-myc/*genetics MH - Risk Factors MH - Survival Rate EDAT- 2008/09/26 09:00 MHDA- 2009/05/08 09:00 CRDT- 2008/09/26 09:00 PHST- 2008/06/10 00:00 [received] PHST- 2008/07/24 00:00 [revised] PHST- 2008/07/27 00:00 [accepted] PHST- 2008/09/26 09:00 [pubmed] PHST- 2009/05/08 09:00 [medline] PHST- 2008/09/26 09:00 [entrez] AID - S0169-5002(08)00414-5 [pii] AID - 10.1016/j.lungcan.2008.07.016 [doi] PST - ppublish SO - Lung Cancer. 2009 Apr;64(1):66-70. doi: 10.1016/j.lungcan.2008.07.016. Epub 2008 Sep 23.